Estradiol (medication)

This article is about the medication. For the natural hormone, see Estradiol.
Clinical data
Pronunciation ESS-tra-DYE-ole[1][2]
Trade names Numerous
AHFS/ Monograph
  • US: X (Contraindicated)
Routes of
By mouth, sublingual, intranasal, topical or transdermal, vaginal, intramuscular or subcutaneous injection (as an ester), subcutaneous implant (pellet)
ATC code G03CA03 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability Oral: <5%[3]
Protein binding ~98%:[3][4]
Albumin: 60%
SHBG: 38%
• Free: 2%
Metabolism Liver (via hydroxylation, sulfation, glucuronidation)
Metabolites Major (90%):[3]
Estrone sulfate
• Estrone glucuronide
• Estradiol glucuronide
Biological half-life Oral: 13–20 hours[3]
Sublingual: 8–18 hours[5]
Topical (gel): 36.5 hours[6]
Excretion Urine: 54%[3]
Feces: 6%[3]
Synonyms 17β-Estradiol; Estra-1,3,5(10)-triene-3,17β-diol
CAS Number 50-28-2 YesY
PubChem (CID) 5757
DrugBank DB00783 YesY
ChemSpider 5554 YesY
UNII 4TI98Z838E YesY
KEGG D00105 YesY
ChEBI CHEBI:16469 YesY
Chemical and physical data
Formula C18H24O2
Molar mass 272.38 g/mol
3D model (Jmol) Interactive image

Estradiol, or oestradiol, is a medication and naturally occurring steroid hormone.[7] It is an estrogen and is used mainly in hormone replacement therapy (HRT) for menopause,[7] hypogonadism, and in transgender women. It is also used in hormonal contraception and sometimes in the treatment of hormone-sensitive cancers like prostate cancer. Estradiol can be taken by mouth, as a gel or patch that is applied to the skin, in through the vagina, by injection into muscle, or through the use of an implant that is placed under the skin, among other routes.[7]

Side effects of estradiol in women include breast tenderness and enlargement, headache, fluid retention, and nausea. Men and children who are exposed to estradiol may develop symptoms of feminization, such as breast development, and men may also experience hypogonadism and infertility. It may increase the risk of endometrial hyperplasia and endometrial cancer in women with an intact uterus if it is not taken together with a progestogen like progesterone. Estradiol should not be used in women who are pregnant or breastfeeding or who have breast cancer.

Estradiol was first isolated in 1935.[8] It first became available as a medication, in the form of estradiol benzoate, a prodrug of estradiol, in 1936.[9] Micronized estradiol, which allowed estradiol to be taken by mouth, was not introduced until 1975.[10] Estradiol is also used as other prodrugs like estradiol valerate and estradiol acetate.[7] Related estrogens such as ethinyl estradiol, which is the most common estrogen in oral contraceptives, and conjugated equine estrogens (marketed as Premarin), are used as medications as well.

Medical uses

Hormone replacement therapy


If severe side effects of low levels of estradiol in a woman's blood are experienced (commonly at the beginning of menopause or after oophorectomy), hormone replacement therapy (HRT) may be prescribed. Such therapy is usually combined with a progestin to reduce the risk of endometrial cancer.[11]


Estradiol is used as an agent of stimulating female puberty induction, as in the treatment of delayed puberty caused by hypogonadism (e.g., in Turner syndrome).

Transgender women

Estrogen therapy is also used as part of the hormone replacement therapy for trans women. Oral, transdermal, implanted, or injectable (subdermal and intramuscular) estradiol is used in higher concentrations during initial treatment and transition; estradiol is continued in lower doses to maintain female-level hormones following sex reassignment surgery.[12]

Birth control

Estradiol is used, in combination with a progestogen and often in ester form, in estradiol-containing oral contraceptives and combined injectable contraceptives. However, a more potent chemical derivative of estradiol, ethinyl estradiol, is by far the most commonly used estrogen in hormonal contraceptives.[13] Combined forms of hormonal contraception contain estrogen and a progestin, which both contribute to the inhibition of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH), which accounts for the ability of these birth control methods to prevent ovulation and thus prevent pregnancy. Other types of hormonal birth control contain only a progestin and no estrogen.[14]

Hormone-sensitive cancers

Estrogen therapy is used to treat advanced prostate cancer and breast cancer, though mostly in the past and with more potent synthetic estrogens than estradiol like ethinyl estradiol and diethylstilbestrol.[15][16] Estradiol undecylate and polyestradiol phosphate are forms of estradiol that have been used in high dosages for the treatment of prostate cancer, however.

Other uses


Estrogen therapy may be used in treatment of infertility in women when there is a need to develop sperm-friendly cervical mucus or an appropriate uterine lining. This is often prescribed in combination with clomifene.

Tall stature

Estrogens have been used to limit final height in adolescent girls with tall stature.[17] They do this by inducing epiphyseal closure and suppressing growth hormone-induced hepatic production (and by extension circulating levels) of insulin-like growth factor-1 (IGF-1).[17]

Medical formulations

Estrogen is marketed in a number of ways to address issues of hypoestrogenism. Thus, there are oral, transdermal, topical, vaginal, intranasal, injectable, and implantable preparations. Furthermore, the estradiol molecule may be linked to an alkyl group at the C17β (and/or C3) position to improve bioavailability and/or duration. Such modifications give rise to forms such as estradiol acetate (oral and vaginal applications) and to estradiol valerate (injectable), which behave as prodrugs of estradiol.

Oral preparations are not necessarily predictably absorbed, and are subject to a first pass through the liver, where they can be metabolized, and also initiate unwanted side effects. Therefore, alternative routes of administration that bypass the liver before primary target organs are hit have been developed. Parenteral routes including transdermal, vaginal, sublingual, intranasal, intramuscular, and subcutaneous are not subject to the initial liver passage.

Not all products are available worldwide. Estradiol is also part of conjugated estrogen preparations, such as Premarin, though it is present only in small quantities in a conjugated form (sodium estradiol sulfate) and is not the major ingredient. (Premarin consists of a large number of estrogen derivatives. As its name alludes to, Premarin is isolated from the urine of pregnant mares.)[18]

List of formulations

Estradiol hemihydrate

A hemihydrate form of estradiol, estradiol hemihydrate (INN), has been marketed under a variety of brand names including Climara, Estraderm, Estralis, Estrasorb, Estreva, Estring, Estrofem, Estrogel, Vagifem, and many others.[19] In terms of activity and bioequivalence, estradiol and its hemihydrate are identical, with the only disparities being an approximate 1% difference in potency by weight (due to the presence of water molecules in the hemihydrate form of the substance) and a slower rate of release with certain formulations of the hemihydrate.[20][21] This is because estradiol hemihydrate is more hydrated than anhydrous estradiol, and for that reason, is highly insoluble in water in comparison, which results in slower absorption rates with specific formulations such as Vagifem, a vaginal tablet form of the drug.[21] Estradiol hemihydrate has also been shown to result in less systemic absorption as a vaginal tablet formulation relative to other topical estradiol formulations such as vaginal creams.[22]


Estradiol should be avoided when there is undiagnosed abnormal genital bleeding, known, suspected or a history of breast cancer, current treatment for metastatic disease, known or suspected estrogen-dependent neoplasia, deep vein thrombosis, pulmonary embolism or history of these conditions, active or recent arterial thromboembolic disease such as stroke, myocardial infarction, liver dysfunction or disease. Estradiol should not be taken by people with a hypersensitivity/allergy or those who are pregnant or are suspected pregnant.[23]

Adverse effects

The most common side effects of estradiol in women include breast tenderness, breast enlargement, headache, fluid retention, and nausea.[3]

A complete list of possible side effects which may occur as a result of use of estradiol or have been associated with estrogen and/or progestogen therapy include:[23][24]

Estrogens should only be used for the shortest possible time and at the lowest effective dose due to these risks. Attempts to gradually reduce the medication via a dose taper should be made every three to six months.[23]


St. John's wort, phenobarbital, carbamazepine and rifampicin decrease the levels of estrogens, such as estradiol, by speeding up their metabolism, whereas erythromycin, cimetidine, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may slow down metabolism, leading to increased levels in the blood plasma.[23] Cimetidine, a known, non-selective inhibitor of CYP450 enzymes, can increase the levels of exogenous, orally-ingested estradiol.[25]


Estradiol is an estrogen, or an agonist of the nuclear estrogen receptors (ERs), the ERα and the ERβ.[7] It is also an agonist of the membrane estrogen receptors (mERs), for instance the GPER.[26][27] Estradiol is much more potent than other natural estrogens like estrone and estriol.[7]


Estrone:Estradiol Ratio[7]
Premenopause 1:2
Postmenopause 2:1
Oral estradiol 5:1
Oral estrone sulfate 5:1
Transdermal estradiol (patch) 1:1
Transdermal estradiol (gel) 1:1
Intranasal estradiol 2:1
Sublingual estradiol 1:3
Vaginal estradiol 1:5
Subcutaneous estradiol (implant) 1:1.5
Intramuscular estradiol 1:2

Different routes of administration of estradiol produce different effects in the body due to differences in the amount of estradiol that is exposed to the liver as well as different levels of estradiol produced.[28]

Estradiol is plasma protein binding loosely to albumin and tightly to sex hormone-binding globulin (SHBG), with approximately 97 to 98% of estradiol bound to plasma proteins.[29] In the circulation, approximately 38% of estradiol is bound to SHBG and 60% is bound to albumin, with 2–3% free.[30]

Oral administration


The oral bioavailability of estradiol in its is usual state is very poor and the hormone must be either micronized or esterified (as in, e.g., estradiol valerate or estradiol acetate) to be bioavailable to any significant extent.[29][31][32] This is because estradiol is extensively metabolized during first-pass metabolism in the intestines and liver, and micronization increases the rate of absorption and improves the metabolic stability of estradiol.[30] As micronization is required for significant bioavailability, all oral estradiol tablets are micronized.[31] Estradiol is rapidly and completely absorbed upon oral administration.[30] This is true for oral doses of 2 mg and 4 mg, but absorption was found to be incomplete for a dose of 8 mg.[30] Although micronized estradiol is well-absorbed orally and has greatly improved bioavailability relative to non-micronized estradiol, its bioavailability is still nonetheless very low due to the extensive first-pass metabolism.[29][31] Around 95% of oral estradiol is metabolized prior to entering systemic circulation,[30] and in accordance, the absolute bioavailability of oral micronized estradiol is between 0.1% and 12%.[29]

A dosage of 1 mg/day oral micronized estradiol results in circulating concentrations of 30–50 pg/mL estradiol and 150–300 pg/mL estrone, while a dosage of 2 mg/day produces circulating levels of 50–180 pg/mL estradiol and 300–850 pg/mL estrone.[33]


When taken orally, most estradiol is converted into estrone and estrone sulfate in the liver during first-pass metabolism.[22][34] Oral estradiol administration produces a plasma estradiol-to-estrone ratio of about 1:5 to 1:7.[35]

About 15% of orally administered estradiol is converted into estrone and 65% is converted into estrone sulfate.[36] About 5% of estrone and 1.4% of estrone can be converted back into estradiol.[36] An additional 21% of estrone sulfate can be converted into estrone, whereas the conversion of estrone to estrone sulfate is approximately 54%.[36] This reversible interconversion between estradiol and estrone is mediated by 17β-hydroxysteroid dehydrogenase,[36] whereas the interconversion between estrone and estrone sulfate is mediated by estrogen sulfotransferase and steroid sulfatase.[37][38]

The terminal half-life of orally administered estradiol is a composite parameter that is dependent on interconversion between estrone and sulfate and glucuronide conjugates and enterohepatic recirculation.[36] It has a range of 13 to 20 hours.[36]


Estrone is approximately 10-fold less potent relative to estradiol as an estrogen,[39] and also has a different binding profile relative to estradiol, for instance, lacking affinity to the GPER.[40] In addition, the resulting supraphysiological levels of estrogen in the liver (4- to 5-fold higher relative to the circulation)[41] increase the risk of blood clots,[42] suppress growth hormone (GH)-mediated insulin-like growth factor 1 (IGF-1) production,[43][44] and increase levels of a variety of binding proteins including thyroid binding globulin (TBG), cortisol binding globulin (CBG), sex hormone binding globulin (SHBG), growth hormone binding protein (GHBP),[45] insulin-like growth factor-binding proteins (IGFBPs),[46] and copper binding protein (CBP),[22][47] but also produce positive blood lipid changes.[34][48]

Sublingual administration

Micronized estradiol tablets can be taken sublingually instead of orally.[49] All estradiol tablets are micronized, as estradiol cannot be absorbed efficiently otherwise.[31] Sublingual ingestion bypasses first-pass metabolism in the intestines and liver.[50] It has been found to result in levels of estradiol and an estradiol-to-estrone ratio that are substantially higher in comparison to oral ingestion.[51] Circulating levels of estradiol are as much as 10-fold higher with sublingual administration relative to oral administration and the absolute bioavailability of estradiol is approximately 5-fold higher.[7] On the other hand, levels of estradiol fall rapidly with sublingual administration, whereas they remain elevated for an extended period of time with oral administration.[7][36] This is responsible for the discrepancy between the maximal estradiol levels achieved and the absolute bioavailability.[7][36]

The rapid and steep fall in estradiol levels with sublingual administration is analogous to the case of intravenous administration of the hormone, in which there is a rapid distribution phase of 6 minutes and terminal disposition phase of only 1 to 2 hours.[7][36][52] In contrast to intravenous and sublingual administration, the terminal half-life of estradiol is 13 to 20 hours with oral administration.[7][36] The difference is due to the fact that, upon oral administration, a large hormonally inert pool of estrogen sulfate and glucuronide conjugates with extended terminal half-lives is reversibly formed from estradiol during first-pass metabolism, and this pool serves as a metabolically resistant and long-lasting circulating reservoir for slow reconversion back into estradiol.[7][36]

Upon sublingual ingestion, a single 0.25 mg tablet of micronized estradiol has been found to produce peak levels of 300 pg/mL estradiol and 60 pg/mL estrone within 1 hour.[7] A higher dose of 1 mg estradiol was found to result in maximum levels of 450 pg/mL estradiol and 165 pg/mL estrone.[7] This was followed by a rapid decline in estradiol levels to 85 pg/mL within 3 hours, whereas the decline in estrone levels was much slower and reached a level of 80 pg/mL after 18 hours.[7]

Although sublingual administration of estradiol has a relatively short duration, the drug can be administered multiple times per day in divided doses to compensate for this.[7] In addition, it is notable that the magnitude of the genomic effects of estradiol (i.e., signaling through the nuclear ERs) appears to be dependent solely on the total exposure as opposed to the duration of exposure.[7] For instance, in both normal human epithelial breast cells and ER-positive breast cancer cells, the rate of breast cell proliferation has been found not to differ with estradiol incubation of 1 nM for 24 hours and incubation of 24 nM for 1 hour.[7] In other words, short-term high concentrations and long-term low concentrations of estradiol appear to have the same degree of effect in terms of genomic estrogenic signaling.[7]

On the other hand, non-genomic actions of estradiol, such as signaling through membrane estrogen receptors like the GPER, may be reduced with short-term high concentrations of estradiol relative to more sustained levels.[7] For instance, although daily intranasal administration of estradiol (which, similarly to sublingual administration, produces extremely high peak levels of estradiol followed by a rapid fall in estradiol levels) is associated in postmenopausal women with comparable clinical effectiveness (e.g., for hot flashes) relative to longer acting routes of estradiol administration, it is also associated with significantly lower rates of breast tension (tenderness and enlargement) relative to longer acting estradiol routes, and this is thought to reflect comparatively diminished non-genomic signaling.[7]

Transdermal administration

See also: Estrogen patch

Transdermal estradiol is available in the forms of topical gels, patches, sprays, and emulsions.

Estradiol patches delivering a daily dosage of 0.05 mg (50 µg) achieve estradiol and estrone levels of 30–65 pg/mL and 40–45 pg/mL, respectively, while a daily dosage of 0.1 mg (100 µg) attains respective levels of 50–90 pg/mL and 30–65 pg/mL of estradiol and estrone.[33]

Once daily administration of 1.25 g gel containing 0.75 mg estradiol (brand name EstroGel) for 2 weeks was found to produce mean peak estradiol and estrone levels of 46.4 pg/mL and 64.2 pg/mL, respectively.[53] The time-averaged levels of circulating estradiol and estrone with this formulation over the 24-hour dose interval were 28.3 pg/mL and 48.6 pg/mL, respectively.[53] Levels of estradiol and estrone are stable and change relatively little over the course of the 24 hours following an administration, indicating a long duration of action.[53] Steady-state levels of estradiol are achieved after three daily administrations.[53] A higher dosage of estradiol gel containing 1.5 mg estradiol per daily administration has been found to produce estradiol levels of 40–100 pg/mL and estrone levels of 90 pg/mL, while 3 mg/daily has been found to result in respective estradiol and estrone levels of 60–140 pg/mL and 45–155 pg/mL.[33]

Transdermal estradiol bypasses the liver and hence first-pass metabolism in a similar but more complete manner relative to sublingual administration. Estradiol patches have been found not to increase the risk of blood clots[42] and to not affect hepatic IGF-1, SHBG, GHBP,[45] IGFBP,[46] or other protein production.[43][44][47] Transdermal administration of estradiol via patch or gel results in a ratio of about 1:1.[36]

Vaginal administration

Vaginal micronized estradiol achieves a far higher estradiol-to-estrone ratio in comparison, with a daily dosage of 0.5 mg resulting in estradiol and estrone levels of 250 pg/mL and 130 pg/mL, respectively.[33] Vaginal micronized estradiol has been found to bypass the liver and first-pass metabolism similarly to transdermal estradiol and in accordance does not affect hepatic protein production at menopausal replacement dosages.[54]

Intramuscular injection

See also: Estrogen ester

Estradiol, in an ester prodrug form such as estradiol cypionate or estradiol valerate, can be administered via intramuscular depot injection.[55][56] In marked contrast to the oral route, the bioavailability of both estradiol and estradiol esters like estradiol valerate is complete (i.e., 100%) via intramuscular administration.[52]

A single 4 mg intramusuclar (i.m.) injection of estradiol cypionate or estradiol valerate results in maximal plasma levels of estradiol of about 250 pg/mL and 390 pg/mL, respectively, with levels declining to 100 pg/mL (which was baseline for estradiol cypionate) by 12–14 days.[57][58] A single 2.5 mg intramuscular injection of estradiol benzoate in individuals being treated with a GnRH analogue (and hence having minimal baseline levels of estrogen) was found to result in serum estradiol levels of >400 pg/mL at 24 hours post-administration.[55] The differences in the serum levels of estradiol achieved with these different estradiol esters may be explained by their different rates of absorption, as their durations and levels attained appear to be inversely proportional. For instance, estradiol benzoate, which has the shortest duration (4–5 days with a single i.m. dose of 5 mg), produces the highest levels of estradiol, while estradiol cypionate, which has the longest duration (~11 days with a single i.m. dose of 5 mg), produces the lowest levels of estradiol).[55] Estradiol valerate was found to have a duration of 7–8 days after a single i.m. dose of 5 mg.[55]

A study of combined high-dose i.m. estradiol valerate and hydroxyprogesterone caproate in peri- and postmenopausal and hypogonadal women (described as a "pseudopregnancy" regimen), with specific dosages of 40 mg weekly and 250 mg weekly, respectively, was found to result in serum estradiol levels of 3028–3226 pg/mL after three months and 2491–2552 pg/mL after six months of treatment from a baseline of 27.8–34.8 pg/mL.[59]

Subcutaneous injection

Subcutaneous and intramuscular injections of estradiol cypionate in an aqueous suspension have been found to show almost identical estradiol levels produced and pharmacokinetics (e.g., duration).[56] However, subcutaneous injections may be easier and less painful to perform, and hence, may result in improved patient satisfaction.[56]

Intravenous injection

The terminal half-life of estradiol administered via intravenous injection is 2 hours in men and 50 minutes in women.[52]

Normal estradiol levels

For comparison, normal menstrual cycle serum levels of estradiol in premenopausal women are 40 pg/mL in the early follicular phase to 250 pg/mL at the middle of the cycle and 100 pg/mL during the mid-luteal phase.[33] Serum estrone levels during the menstrual cycle range from 40 to 170 pg/mL, which parallels the serum levels of estradiol.[33] Mean levels of estradiol in premenopausal women are between 80 and 150 pg/mL according to different sources.[57][60][61] The estradiol-to-estrone ratio in premenopausal women is higher than 1:1.[33] In postmenopausal women, the serum levels of estradiol are below 15 pg/ml and the average levels of estrone are about 30 pg/ml; the estradiol-to-estrone ratio is reversed to less than 1:1.[33]


Estradiol is an estrane (C18) steroid.[7] It is also known as 17β-estradiol (to distinguish it from 17α-estradiol) or as estra-1,3,5(10)-triene-3,17β-diol. It has two hydroxyl groups, one at the C3 position and the other at the 17β position, as well as three double bonds in the A ring. Due to its two hydroxyl groups, estradiol is often abbreviated as E2. The structurally related estrogens, estrone (E1), estriol (E3), and estetrol (E4) have one, three, and four hydroxyl groups, respectively.


A variety of C17β and/or C3 ester prodrugs of estradiol, such as estradiol acetate, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enanthate, estradiol undecylate, estradiol valerate, and polyestradiol phosphate (an estradiol ester in polymeric form), among many others, have been developed and introduced for medical use as estrogens. The alkylating antineoplastic agent estramustine is also an estradiol ester, but with a nitrogen mustard moiety as the ester, and is used in the treatment of prostate cancer. Cloxestradiol acetate and promestriene are ether prodrugs of estradiol that have been introduced for medical use as estrogens as well, although they are little known and rarely used.

Synthetic derivatives of estradiol used as estrogens include ethinyl estradiol, ethinyl estradiol sulfonate, mestranol, methylestradiol, moxestrol, and quinestrol, all of which are 17α-substituted estradiol derivatives. Synthetic derivatives of estradiol used in scientific research include 8β-VE2 and 16α-LE2.


Estradiol was first isolated in 1935.[8] It was also originally known as dihydroxyestrin or alpha-estradiol.[62][63] It was first marketed, as estradiol benzoate, in 1936.[9] Estradiol was also marketed in the 1930s under brand names such as Progynon-DH, Ovocylin, and Dimenformon.[62][63] Micronized estradiol, via the oral route, was first evaluated in 1972,[64] and this was followed by the evaluation of vaginal and intranasal micronized estradiol in 1977.[65] Oral micronized estradiol was first approved in the United States under the brand name Estrace in 1975.[10]

Society and culture

Generic name

Estradiol is the generic name of estradiol in English and the INN, USAN, USP,[66] BAN, DCF, and JAN of the drug, while estradiolo is the name of estradiol in Italian and the DCIT.[67][19][68][69] It is also formally referred to as estradiolum in Latin, whereas its generic name remains unchanged as estradiol in Spanish, Portuguese, French, and German.[67][19] Oestradiol was the former BAN of estradiol,[69] but it was changed to estradiol.[67]

Brand names

Estradiol is marketed under a large number of brand names throughout the world.[19][67] Examples of major brand names in which estradiol has been marketed in include Climara, Climen, Dermestril, Divigel, Estrace, Estraderm, Estraderm TTS, Estradot, Estreva, Estrimax, Estring, Estrofem, Estrogel, Evorel, Fem7 (or FemSeven), Menorest, Oesclim, Oestrogel, Sandrena, Systen, and Vagifem.[19][67] Estradiol valerate is marketed mainly as Progynova and Progynon-Depot, while it is marketed as Delestrogen in the U.S.[19][70] Estradiol cypionate is used mainly in the U.S. and is marketed under the brand name Depo-Estradiol.[19][70] Estradiol acetate is available as Femtrace, Femring, and Menoring.[70]

Estradiol is also widely available in combination with progestogens.[67] It is available in combination with norethisterone acetate under the major brand names Activelle, Cliane, Estalis, Eviana, Evorel Conti, Evorel Sequi, Kliogest, Novofem, Sequidot, and Trisequens; with drospirenone as Angeliq; with dydrogesterone as Femoston, Femoston Conti; and with nomegestrol acetate as Zoely.[67] Estradiol valerate is available with cyproterone acetate as Climen; with dienogest as Climodien and Qlaira; with norgestrel as Cyclo-Progynova and Progyluton; with levonorgestrel as Klimonorm; with medroxyprogesterone acetate as Divina and Indivina; and with norethisterone enanthate as Mesigyna and Mesygest.[67] Estradiol cypionate is available with medroxyprogesterone acetate as Cyclo-Provera, Cyclofem, Feminena, Lunelle, and Novafem;[71] estradiol enanthate with algestone acetophenide as Deladroxate, Nomagest, and Novular and with algestone acetonide as Topasel and Yectames;[67] [72][73] and estradiol benzoate is marketed with progesterone as Mestrolar and Nomestrol.[67]

Estradiol valerate is also widely available in combination with prasterone enanthate (DHEA enanthate) under the brand name Gynodian Depot.[67]


United States

Estradiol is available in the United States in the form of oral tablets (Gynodiol, Innofem, generics), transdermal patches (Alora, Climara, Esclim, Estraderm, Fempatch, Menostar, Minivelle, Vivelle, Vivelle-Dot, generics), topical gels (Divigel, Elestrin, Estrogel), topical sprays (Evamist), vaginal tablets (Vagifem, generics), vaginal creams (Estrace), and vaginal rings (Estrace).[70] Topical creams that contain estradiol are generally regulated as cosmetics rather than as drugs in the U.S. and hence are readily available over-the-counter and may be purchased without a prescription on the Internet.[74] Estradiol is also available as estradiol hemihydrate in the form of a topical emulsion (Estrasorb), estradiol acetate in the form of oral tablets (Femtrace) and vaginal rings (Femring), and estradiol valerate and estradiol cypionate in oil for intramuscular injection (Delestrogen and Depo-Estradiol, respectively).[70] Oral estradiol valerate and other intramuscular esters like estradiol benzoate, estradiol enanthate, and estradiol undecylate all are not approved for use in the U.S.[70] Polyestradiol phosphate (Estradurin), an estradiol ester in polymer form and a very long-lasting intramuscular prodrug of estradiol, was formerly marketed in the U.S. for the treatment of prostate cancer but was discontinued.[70]

Estradiol is also available in the U.S. in combination with progestogens for the treatment of menopausal symptoms.[70] It is available in the form of oral tablets in combination with drospirenone (Angeliq) and norethisterone acetate (Activella, Amabelz) and in the form of transdermal patches in combination with levonorgestrel (Climara Pro) and norethisterone acetate (Combipatch).[70] It was also previously available in oral tablet form in combination with norgestimate (Prefest), but this product is no longer available.[70] A combination formulation of estradiol and progesterone micronized in oil-filled oral capsules (TX-001HR) is currently under development in the U.S. for the treatment of menopausal symptoms and endometrial hyperplasia, though it has yet to be approved or introduced.[75][76] In addition to the treatment of menopausal symptoms, estradiol is available in oral tablet form as estradiol valerate in combination with dienogest (Natazia).[70] Estradiol was also available as estradiol cypionate in combination with medroxyprogesterone acetate as a once-monthly intramuscular combined injectable contraceptive (Lunelle), but this product was discontinued.[70] A combination of estradiol cypionate and testosterone cypionate (Depo-Testadiol) and a combination of estradiol valerate and testosterone enanthate (Ditate-DS) were formerly marketed in the U.S. but have also been discontinued.[70]

Estradiol and estradiol esters are also available in custom preparations from compounding pharmacies in the U.S.[77] This includes subcutaneous pellet implants.[78]

Other countries

Estradiol and/or its esters are widely available in countries throughout the world in a variety of formulations. For an extensive list of countries that they are marketed in along with the associated brand names, see here.


  1. Susan M. Ford; Sally S. Roach (7 October 2013). Roach's Introductory Clinical Pharmacology. Lippincott Williams & Wilkins. pp. 525–. ISBN 978-1-4698-3214-2.
  2. Maryanne Hochadel; Mosby (1 April 2015). Mosby's Drug Reference for Health Professions. Elsevier Health Sciences. pp. 602–. ISBN 978-0-323-31103-8.
  3. 1 2 3 4 5 6 7 Stanczyk, Frank Z.; Archer, David F.; Bhavnani, Bhagu R. (2013). "Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment". Contraception. 87 (6): 706–727. doi:10.1016/j.contraception.2012.12.011. ISSN 0010-7824.
  4. Tommaso Falcone; William W. Hurd (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. pp. 22–. ISBN 0-323-03309-1.
  5. Price, T; Blauer, K; Hansen, M; Stanczyk, F; Lobo, R; Bates, G (1997). "Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17-estradiol". Obstetrics & Gynecology. 89 (3): 340–345. doi:10.1016/S0029-7844(96)00513-3. ISSN 0029-7844.
  6. Naunton, Mark; Al Hadithy, Asmar F. Y.; Brouwers, Jacobus R. B. J.; Archer, David F. (2006). "Estradiol gel". Menopause. 13 (3): 517–527. doi:10.1097/01.gme.0000191881.52175.8c. ISSN 1072-3714.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  8. 1 2 Fritz F. Parl (2000). Estrogens, Estrogen Receptor and Breast Cancer. IOS Press. pp. 4–. ISBN 978-0-9673355-4-4.
  9. 1 2 Enrique Raviña; Hugo Kubinyi (16 May 2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 175. ISBN 978-3-527-32669-3. Retrieved 20 May 2012.
  10. 1 2
  11. Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 434, 444. ISBN 3-8047-1763-2.
  13. Evans G, Sutton EL (May 2015). "Oral contraception". Med Clin North Am. 99 (3): 479–503. doi:10.1016/j.mcna.2015.01.004. PMID 25841596.
  14. Glasier, Anna (2010). "Contraception". In Jameson, J. Larry; De Groot, Leslie J. Endocrinology (6th ed.). Philadelphia: Saunders Elsevier. pp. 2417–2427. ISBN 978-1-4160-5583-9.
  15. Ockrim JL; Lalani el-N; Kakkar AK; Abel PD (August 2005). "Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism". J. Urol. 174 (2): 527–33; discussion 532–3. doi:10.1097/01.ju.0000165567.99142.1f. PMID 16006886.
  16. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, Lo Castro M, Vidali G, Castagnetta L (March 1994). "Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells". Cancer Res. 54 (5): 1190–3. PMID 8118804.
  17. 1 2 Juul A (2001). "The effects of oestrogens on linear bone growth". Hum. Reprod. Update. 7 (3): 303–13. PMID 11392377.
  18. Premarin Official FDA information, side effects and uses.
  19. 1 2 3 4 5 6 7 Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. pp. 404–406. ISBN 978-3-88763-075-1. Retrieved 13 September 2012.
  20. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research On Cancer (2007). Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. World Health Organization. p. 384. ISBN 978-92-832-1291-1. Retrieved 13 September 2012.
  21. 1 2 Archana Desai; Mary Lee (7 May 2007). Gibaldi's Drug Delivery Systems in Pharmaceutical Care. ASHP. p. 337. ISBN 978-1-58528-136-7. Retrieved 13 September 2012.
  22. 1 2 3 Rebekah Wang-Cheng; Joan M. Neuner; Vanessa M. Barnabei (2007). Menopause. ACP Press. pp. 91–. ISBN 978-1-930513-83-9.
  23. 1 2 3 4 Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). Retrieved 27 November 2016.
  24. Pfizer (August 2008). "ESTRING (estradiol vaginal ring)" (PDF).
  25. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH (February 2001). "Role of cytochrome P450 in estradiol metabolism in vitro". Acta Pharmacol. Sin. 22 (2): 148–54. PMID 11741520.
  26. Soltysik K, Czekaj P (April 2013). "Membrane estrogen receptors - is it an alternative way of estrogen action?". J. Physiol. Pharmacol. 64 (2): 129–42. PMID 23756388.
  27. Prossnitz ER, Barton M (May 2014). "Estrogen biology: New insights into GPER function and clinical opportunities". Mol. Cell. Endocrinol. 389 (1–2): 71–83. doi:10.1016/j.mce.2014.02.002. PMC 4040308Freely accessible. PMID 24530924.
  28. na. Newnes. pp. 486–. ISBN 978-0-444-54286-1.
  29. 1 2 3 4 O'Connell MB (1995). "Pharmacokinetic and pharmacologic variation between different estrogen products". J Clin Pharmacol. 35 (9 Suppl): 18S–24S. PMID 8530713.
  30. 1 2 3 4 5 Kuhnz, W.; Blode, H.; Zimmermann, H. (1993). "Pharmacokinetics of Exogenous Natural and Synthetic Estrogens and Antiestrogens". 135 / 2: 261–322. doi:10.1007/978-3-642-60107-1_15. ISSN 0171-2004.
  31. 1 2 3 4 A. Wayne Meikle (1 June 1999). Hormone Replacement Therapy. Springer Science & Business Media. pp. 380–. ISBN 978-1-59259-700-0.
  32. V. H. T. James; J. R. Pasqualini (22 October 2013). Hormonal Steroids: Proceedings of the Sixth International Congress on Hormonal Steroids. Elsevier Science. pp. 821–. ISBN 978-1-4831-9067-9.
  33. 1 2 3 4 5 6 7 8 Rogerio A. Lobo (5 June 2007). Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Academic Press. pp. 771–. ISBN 978-0-08-055309-2.
  34. 1 2 John J.B. Anderson; Sanford C. Garner (24 October 1995). Calcium and Phosphorus in Health and Disease. CRC Press. pp. 215–216. ISBN 978-0-8493-7845-4.
  35. Eef Hogervorst (24 September 2009). Hormones, Cognition and Dementia: State of the Art and Emergent Therapeutic Strategies. Cambridge University Press. pp. 82–. ISBN 978-0-521-89937-6.
  36. 1 2 3 4 5 6 7 8 9 10 11 12 Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 235–237,268,271. ISBN 978-3-642-60107-1.
  37. Jose Russo; Irma H. Russo (28 June 2011). Molecular Basis of Breast Cancer: Prevention and Treatment. Springer Science & Business Media. pp. 92–. ISBN 978-3-642-18736-0.
  38. Sue E. Huether; Kathryn L. McCance (27 December 2013). Understanding Pathophysiology. Elsevier Health Sciences. pp. 845–. ISBN 978-0-323-29343-3.
  39. Ruggiero RJ, Likis FE (2002). "Estrogen: physiology, pharmacology, and formulations for replacement therapy". Journal of Midwifery & Women's Health. 47 (3): 130–8. doi:10.1016/s1526-9523(02)00233-7. PMID 12071379.
  40. Prossnitz ER, Arterburn JB, Sklar LA (2007). "GPR30: A G protein-coupled receptor for estrogen". Mol. Cell. Endocrinol. 265-266: 138–42. doi:10.1016/j.mce.2006.12.010. PMC 1847610Freely accessible. PMID 17222505.
  41. Marc A. Fritz; Leon Speroff (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 753–. ISBN 978-1-4511-4847-3.
  42. 1 2 Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd HL (1988). "Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration". J. Lab. Clin. Med. 111 (2): 224–8. PMID 2448408.
  43. 1 2 Weissberger AJ, Ho KK, Lazarus L (1991). "Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women". J. Clin. Endocrinol. Metab. 72 (2): 374–81. doi:10.1210/jcem-72-2-374. PMID 1991807.
  44. 1 2 Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E (2007). "Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study". Clin. Endocrinol. (Oxf). 66 (5): 626–31. doi:10.1111/j.1365-2265.2007.02783.x. PMID 17492948.
  45. 1 2 Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK (2003). "Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women". Clin. Endocrinol. (Oxf). 59 (6): 690–8. doi:10.1046/j.1365-2265.2003.01907.x. PMID 14974909.
  46. 1 2 Isotton, A. L.; Wender, M. C. O.; Casagrande, A.; Rollin, G.; Czepielewski, M. A. (2011). "Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study" (PDF). European Journal of Endocrinology. 166 (2): 207–213. doi:10.1530/EJE-11-0560. ISSN 0804-4643. PMID 22108915.
  47. 1 2 Jasonni VM, Bulletti C, Naldi S, Ciotti P, Di Cosmo D, Lazzaretto R, et al. (1988). "Biological and endocrine aspects of transdermal 17 beta-oestradiol administration in post-menopausal women". Maturitas. 10 (4): 263–70. doi:10.1016/0378-5122(88)90062-x. PMID 3226336.
  48. Dansuk R, Unal O, Karageyim Y, Esim E, Turan C (2004). "Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women". Gynecol. Endocrinol. 18 (5): 233–9. doi:10.1080/09513590410001715199. PMID 15346658.
  49. Casper RF, Yen SS (1981). "Rapid absorption of micronized estradiol-17 beta following sublingual administration". Obstet Gynecol. 57 (1): 62–4. PMID 7454177.
  50. Pines A, Averbuch M, Fisman EZ, Rosano GM (1999). "The acute effects of sublingual 17beta-estradiol on the cardiovascular system". Maturitas. 33 (1): 81–5. doi:10.1016/s0378-5122(99)00036-5. PMID 10585176.
  51. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW (1997). "Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 beta-estradiol". Obstet Gynecol. 89 (3): 340–5. doi:10.1016/S0029-7844(96)00513-3. PMID 9052581.
  52. 1 2 3 Düsterberg B, Nishino Y (1982). "Pharmacokinetic and pharmacological features of oestradiol valerate". Maturitas. 4 (4): 315–24. PMID 7169965.
  53. 1 2 3 4 "EstroGel® 0.06% (Estradiol Gel) for Topical Use FDA Label" (PDF). Food and Drug Administration. 2014. Retrieved 17 October 2016.
  54. Hall G, Blombäck M, Landgren BM, Bremme K (2002). "Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women". Fertil. Steril. 78 (6): 1172–7. doi:10.1016/s0015-0282(02)04285-1. PMID 12477507.
  55. 1 2 3 4 Oriowo MA, Landgren BM, Stenström B, Diczfalusy E (April 1980). "A comparison of the pharmacokinetic properties of three estradiol esters". Contraception. 21 (4): 415–24. doi:10.1016/s0010-7824(80)80018-7. PMID 7389356.
  56. 1 2 3 Sierra-Ramírez JA, Lara-Ricalde R, Lujan M, Velázquez-Ramírez N, Godínez-Victoria M, Hernádez-Munguía IA, et al. (2011). "Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg)". Contraception. 84 (6): 565–70. doi:10.1016/j.contraception.2011.03.014. PMID 22078184.
  57. 1 2 M. Notelovitz; P.A. van Keep (6 December 2012). The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause, held at Lake Buena Vista, Florida, October 28–November 2, 1984. Springer Science & Business Media. pp. 397, 399. ISBN 978-94-009-4145-8. [...] following the menopause, circulating estradiol levels decrease from a premenopausal mean of 120 pg/ml to only 13 pg/ml.
  58. Nagrath Arun; Malhotra Narendra; Seth Shikha (15 December 2012). Progress in Obstetrics and Gynecology--3. Jaypee Brothers Medical Publishers Pvt. Ltd. pp. 416–418. ISBN 978-93-5090-575-3.
  59. Ulrich U, Pfeifer T, Lauritzen C (1994). "Rapid increase in lumbar spine bone density in osteopenic women by high-dose intramuscular estrogen-progestogen injections. A preliminary report". Horm. Metab. Res. 26 (9): 428–31. doi:10.1055/s-2007-1001723. PMID 7835827.
  60. C. Christian; B. von Schoultz (15 March 1994). Hormone Replacement Therapy: Standardized or Individually Adapted Doses?. CRC Press. pp. 60–. ISBN 978-1-85070-545-1. The mean integrated estradiol level during a full 28-day normal cycle is around 80 pg/ml.
  61. Eugenio E. Müller; Robert M. MacLeod (6 December 2012). Neuroendocrine Perspectives. Springer Science & Business Media. pp. 121–. ISBN 978-1-4612-3554-5. [...] [premenopausal] mean [estradiol] concentration of 150 pg/ml [...]
  62. 1 2 Fluhmann CF (1938). "Estrogenic Hormones: Their Clinical Usage". Cal West Med. 49 (5): 362–6. PMC 1659459Freely accessible. PMID 18744783.
  63. 1 2 Reilly WA (1941). "Estrogens: Their Use in Pediatrics". Cal West Med. 55 (5): 237–9. PMC 1634235Freely accessible. PMID 18746057.
  64. Martin PL, Burnier AM, Greaney MO (1972). "Oral menopausal therapy using 17- micronized estradiol. A preliminary study of effectiveness, tolerance and patient preference". Obstet Gynecol. 39 (5): 771–4. PMID 5023261.
  65. Rigg LA, Milanes B, Villanueva B, Yen SS (1977). "Efficacy of intravaginal and intranasal administration of micronized estradiol-17beta". J. Clin. Endocrinol. Metab. 45 (6): 1261–4. doi:10.1210/jcem-45-6-1261. PMID 591620.
  67. 1 2 3 4 5 6 7 8 9 10 11
  68. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 897–. ISBN 978-1-4757-2085-3.
  69. 1 2 I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 206–. ISBN 978-94-011-4439-1.
  70. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Drugs@FDA: FDA Approved Drug Products" (HTML). United States Food and Drug Administration. Retrieved 16 November 2016.
  71. Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". J Obstet Gynaecol (Lahore). 4 Suppl 1: S1–34. doi:10.3109/01443619409027641. PMID 12290848.
  73. Rowlands, S (2009). "New technologies in contraception". BJOG: An International Journal of Obstetrics & Gynaecology. 116 (2): 230–239. doi:10.1111/j.1471-0528.2008.01985.x. ISSN 1470-0328.
  74. Fugh-Berman A, Bythrow J (2007). "Bioidentical hormones for menopausal hormone therapy: variation on a theme". J Gen Intern Med. 22 (7): 1030–4. doi:10.1007/s11606-007-0141-4. PMC 2219716Freely accessible. PMID 17549577.
  76. Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–16. doi:10.1097/GME.0000000000000467. PMC 4666011Freely accessible. PMID 25944519.
  77. Kaunitz AM, Kaunitz JD (2015). "Compounded bioidentical hormone therapy: time for a reality check?". Menopause. 22 (9): 919–20. doi:10.1097/GME.0000000000000484. PMID 26035149.
  78. Pinkerton JV, Pickar JH (2016). "Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy". Menopause. 23 (2): 215–23. doi:10.1097/GME.0000000000000523. PMC 4927324Freely accessible. PMID 26418479.

This article is issued from Wikipedia - version of the 11/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.